Most pro-hemp initiatives in the United States are now focused on defining and distinguishing between industrial hemp and marijuana. Some pro-hemp supporters would like to move the control of U.S. hemp production from the DEA to the USDA. Proponents of legalizing hemp also argue that new technology to distinguish THC levels both in the field and from the air will allow for adequate production enforcement.
Hemp, grown under license mostly in Canada, is the most publicized “new” crop in North America. Until very recently the prohibition against drug forms of the plant prevented consideration of cultivation of fiber and oilseed cultivars in Canada. However, in the last 10 years three key developments occurred: (1) much-publicized recent advances in the legal cultivation of hemp in western Europe, especially for new value-added products; (2) enterprising farmers and farm groups became convinced of the agricultural potential of hemp in Canada, and obtained permits to conduct experimental cultivation; and (3) lobby groups convinced the government of Canada that narcotic forms of the hemp plant are distinct and distinguishable from fiber and oilseed forms. In March 1998, new regulations (under the Controlled Drugs and Substances Act) were provided to allow the commercial development of a hemp industry in Canada, and since then more than a thousand licenses have been issued. Hectares licensed for cultivation for 1998–2001 were respectively, 2,500, 14,200, 5,487, and 1,355, the decreasing trend due to a glut of seed produced in 1999 and pessimism over new potential regulations barring exports to the US. Information on the commercial potential of hemp in Canada is in Blade (1998), Marcus (1998), and Pinfold Consulting (1998). In the US, a substantial trade in hemp products has developed, based on imports of hemp fiber, grain, and oil. The American agricultural community has observed this, and has had success at the state level in persuading legislators of the advisability of experimental hemp cultivation as a means of evaluating the wisdom of re-establishing American hemp production. However, because of opposition by the federal government, to date there has only been a small experimental plot in Hawaii. Information on the commercial potential of hemp in the US is presented in the following.
Access to viable seed may present a challenge for research programs and commercial growers. To implement commercial and research hemp programs, farmers need access to seeds that are guaranteed to produce plants that fall under the legal definition of hemp. These seeds can be difficult to obtain, however, because hemp is still regulated under the federal Controlled Substances Act. In response to this problem, Colorado’s governor sent a letter to the U.S. secretary of agriculture in 2014 requesting the federal government address hemp seed regulations.
Quality is a particular concern, because cannabis plants easily soak up heavy metals from pesticides and other contaminants, Marcu says. If you are buying online, look for a company that documents how it tests its products. (If the website doesn’t indicate this, call and ask.) “Buying from a reputable manufacturer is crucial, because it matters how the plant is cultivated and processed,” Dr. Maroon says. One clue that a company is cutting corners: too low a cost. Good CBD is pricey—a bottle of high-quality capsules is sold in Cohen’s office for $140. But for many, it’s worth the money. Roth spent $60 on her tiny bottle. But when her energy returned the day she started taking CBD, she decided that was a small price to pay.
In the meantime, some physicians are forging ahead — and cashing in. Joe Cohen is a doctor at Holos Health, a medical marijuana clinic in Boulder. I asked him what CBD is good for, and he read me a long list of conditions: pain, inflammation, nausea, vomiting, intestinal cramping, anxiety, psychosis, muscle spasms, hyperactive immune systems, nervous system degeneration, elevated blood sugar and more. He also claimed that CBD has anti-cancer properties and can regenerate brain cells and reduce the brain’s levels of amyloid beta — a kind of protein that’s been linked to Alzheimer’s disease. I asked for references, noting that most of these weren’t listed in the Academies report or a similar review published in the Journal of the American Medical Association. “I think you just have to Google search it,” he said. It’s true that a preliminary study found hints that cannabinoids might reduce beta amyloid proteins in human brain cells, but the study was done in cells grown in a lab, not in people. As for cancer, the FDA sent warning letters last year to four companies that were selling products that claimed to “prevent, diagnose, treat or cure” cancer.
All this talk about THC lands us nicely in the whole “Full Spectrum vs. Pure Isolate” debate. Once you begin shopping for CBD products, you’ll notice a lot of jargon that gets thrown around without much explanation. Now that we’ve introduced THC into the conversation, we can talk about the difference between, and relative benefits of, Full Spectrum CBD and CBD Isolate (and the lesser-known contender: Broad Spectrum).
Recent European Commission proposals to change its subsidy regime for hemp contained the following negative evaluation of hemp seed: “The use of hemp seed ... would, however, even in the absence of THC, contribute towards making the narcotic use of cannabis acceptable... In this light, subsidy will be denied producers who are growing grain for use in human nutrition and cosmetics.”
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
38 states and Puerto Rico considered legislation related to industrial hemp in 2017. These bills ranged from clarifying existing laws to establishing new licensing requirements and programs. At least 15 states enacted legislation in 2017 — Arkansas, Colorado, Florida, Hawaii, North Dakota, Nevada, New York, Oregon, South Carolina, Tennessee, Virginia, Washington, West Virginia, Wisconsin and Wyoming. Florida, Wisconsin and Nevada authorized new research or pilot programs. The governors of Arizona and New Mexico vetoed legislation, which would have established new research programs.
In a randomized clinical trial, researchers compared the safety and effectiveness of orally administered Cannabis extract (2.5 mg THC and 1 mg CBD), THC (2.5 mg), or placebo for the treatment of cancer-related anorexia-cachexia in 243 patients with advanced cancer who received treatment twice daily for 6 weeks. Results demonstrated that although these agents were well tolerated by these patients, no differences were observed in patient appetite or quality of life among the three groups at this dose level and duration of intervention.
Content updates feature essential information related to the state’s commercial cannabis regulations and guidelines, the licensing application process, and announcements from the state’s three cannabis licensing authorities and business partners. Links to each state agency’s cannabis information are listed towards to the bottom of the homepage under the “Collaborating State Agencies” header.
Under federal law, cannabis (from which both CBD and marijuana are derived) is illegal everywhere, although the laws against it aren’t generally enforced in states that have legalized marijuana. Some manufacturers claim that CBD culled from legally imported industrial hemp, which has little to no THC, is fine to ship across the U.S., but many experts disagree, noting that because hemp comes from the same species as marijuana, cannabis sativa, all CBD falls under the DEA’s Schedule 1 designation. “This creative interpretation of the law runs afoul of reality,” says the Brookings Institution, a Washington, DC, think tank.
An absence of such fiber-strain traits as tallness, limited branching, long internodes, and very hollow stems, is characteristic of narcotic strains. Drug forms have historically been grown in areas south of the north-temperate zone, often close to the equator, and are photoperiodically adapted to a long season. When grown in north-temperate climates maturation is much-delayed until late fall, or the plants succumb to cold weather before they are able to produce seeds. Unlike fiber strains that have been selected to grow well at extremely high densities, drug strains tend to be less persistent when grown in high concentration (de Meijer 1994). Drug strains can be very similar in appearance to fiber strains. However, a characteristic type of narcotic plant was selected in southern Asia, particularly in India and neighboring countries. This is dioecious, short (about a meter in height), highly branched, with large leaves (i.e. wide leaflets), and it is slow to mature. The appearance is rather like a short, conical Christmas tree.
The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, gender, religion, age, disability, political beliefs, sexual orientation, and marital or family status. (Not all prohibited bases apply to all programs.) Many materials can be made available in alternative formats for ADA clients. To file a complaint of discrimination, write USDA, Office of Civil Rights, Room 326-W, Whitten Building, 14th and Independence Avenue, SW, Washington, DC 20250-9410 or call 202-720-5964.
In recent decades, the neurobiology of cannabinoids has been analyzed.[12-15] The first cannabinoid receptor, CB1, was identified in the brain in 1988. A second cannabinoid receptor, CB2, was identified in 1993. The highest expression of CB2 receptors is located on B lymphocytes and natural killer cells, suggesting a possible role in immunity. Endogenous cannabinoids (endocannabinoids) have been identified and appear to have a role in pain modulation, control of movement, feeding behavior, mood, bone growth, inflammation, neuroprotection, and memory.